Applying New Stem Cell Science to Reboot the Immune System

Magenta Therapeutics (NASDAQ: MGTA) is a biotechnology company developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of transplant medicine, Magenta Therapeutics is pioneering an integrated approach to extend the curative power of bone marrow transplant to more patients.

Year Invested: 2016
Location: Cambridge, Mass.

Recent News

March 19, 2019
Magenta Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights

March 6, 2019
Magenta Therapeutics to Present at Investor Conferences in March

February 25, 2019
Magenta Therapeutics Presents Preclinical Data on Targeted Non-Genotoxic Conditioning Programs, Including First Conditioning Development Candidate

Read More News

Associated Team Members

Alexis Borisy

Stephen Sherwin, M.D.
Venture Partner